Cover Image

Intravitreal sustained-release dexamethasone implant for the treatment of postoperative cystoid macular edema following vitrectomy

Previous findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. Th...

Full description

Saved in:
Bibliographic Details
Main Authors: Huynh, Elisa (Author) , Chronopoulos, Argyrios (Author) , Langbein, Lucrezia (Author) , Hattenbach, Lars-Olof (Author)
Format: Article (Journal)
Language:English
Published: December 2026
In: International ophthalmology
Year: 2026, Volume: 46, Issue: 1, Pages: 1-8
ISSN:1573-2630
DOI:10.1007/s10792-026-04053-3
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10792-026-04053-3
Get full text
Author Notes:Elisa Huynh, Argyrios Chronopoulos, Lucrezia Langbein, Lars-Olof Hattenbach
Description
Summary:Previous findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. This study aims to evaluate the efficacy of DEX implants in patients with persistent postoperative CME following vitrectomy, and to assess differences in treatment response regarding surgical indication, phakic status, and prior treatment received before DEX.
Item Description:Online veröffentlicht: 26. März 2026
Gesehen am 23.04.2026
Physical Description:Online Resource
ISSN:1573-2630
DOI:10.1007/s10792-026-04053-3

Similar Items